Fisher & Paykel Healthcare Corporation Limited (FSPKF)
| Market Cap | 15.84B +24.5% |
| Revenue (ttm) | 1.32B +14.2% |
| Net Income | 267.70M +24.2% |
| EPS | 0.44 +24.1% |
| Shares Out | n/a |
| PE Ratio | 61.39 |
| Forward PE | 92.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4 |
| Open | 30.21 |
| Previous Close | 26.99 |
| Day's Range | 26.99 - 30.21 |
| 52-Week Range | 19.01 - 30.21 |
| Beta | 0.93 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 25, 2026 |
About FSPKF
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilatio... [Read more]
Financial Performance
In fiscal year 2026, FSPKF's revenue was 2.31 billion, an increase of 14.22% compared to the previous year's 2.02 billion. Earnings were 468.50 million, an increase of 24.20%.
Financial numbers in NZD Financial StatementsNews
Blue-chip stocks lift New Zealand sharemarket to record close as oil price falls – Market close
Fisher & Paykel Healthcare accounted for $25.08m of trading.
Blue chips in demand as NZ sharemarket reaches new high, up 1.3%
Fisher & Paykel Healthcare gained 56c to $48.54, accounting for $25.08m of trade.
Fisher & Paykel Healthcare shares fall, dragging the NZX 50 lower
Fisher & Paykel Healthcare drags the NZX 50 down 0.71%.
F&P Healthcare helps drag NZ sharemarket down
The S&P/NZX 50 Index closed at 13,698.63, down 98.37 points or 0.71%.
Fisher & Paykel Healthcare again dominant player in market rise – Market close
The S&P/NZX50 Index closed at 13,749.35, up 57.49 points or 0.42%.
Fisher & Paykel drives NZX higher despite other markets falling – Market close
The S&P/NZX50 Index closed at 13,691.85, up 7.8 points or 0.06%.
NZ sharemarket’s flat spell continues as S&P 500 and Nasdaq hit record highs
Ryman declined to a 16-year low, while Fisher & Paykel Healthcare is at an all-time high.
Sharemarket rebounds 1.1% as Fisher & Paykel Healthcare hits record – Market close
The Warehouse returned to profit with an $11.23m annual net result.
NZ sharemarket up 0.8%, F&P Healthcare leads the way – Market close
The S&P/NZX50 Index closed at 13,992.72, up 110.84 points or 0.8%.
Fisher & Paykel Healthcare Corporation Transcript: AGM 2026
Strong financial growth was reported, with revenue and profit up significantly and dividends increased. Strategic investments in R&D and global manufacturing expansion were highlighted, alongside robust governance and risk management. Shareholders approved all resolutions, with active engagement on remuneration and supply chain issues.
Fisher & Paykel Healthcare Corporation Slides: FY 2026
Fisher & Paykel Healthcare Corporation has posted slides in relation to its FY 2026 quarterly earnings report, which was published on August 24, 2026.
Fisher & Paykel Healthcare upgrades 2027 earnings guidance
Fisher & Paykel Healthcare cites strong hospital demand as a growth driver.